Fairmount Funds Management LLC Astria Therapeutics, Inc. Transaction History
Fairmount Funds Management LLC
- $294 Million
- Q1 2025
A detailed history of Fairmount Funds Management LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,554,129 shares of ATXS stock, worth $14.5 Million. This represents 6.47% of its overall portfolio holdings.
Number of Shares
3,554,129
Previous 3,554,129
-0.0%
Holding current value
$14.5 Million
Previous $31.3 Million
39.39%
% of portfolio
6.47%
Previous 6.29%
Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
119Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$26.5 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$20.9 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$17.1 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$15.6 Million4.93% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$14.4 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $62.1M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...